Gene
PLCG2
PLCG2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Actionable biomarkers (1), Trial mentions (8), Target-disease associations (422), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention PLCG2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 10 at the structurally incomplete recent edge.
PLCG2 has 8 trial mentions across 7 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 8 of 11,460 | 0.07% |
| 2022 | 1 of 8,285 | 0.01% | 15 of 13,598 | 0.11% |
| 2021 | 1 of 8,692 | 0.01% | 14 of 15,045 | 0.09% |
| 2020 | 2 of 7,640 | 0.03% | 7 of 14,459 | 0.05% |
| 2019 | 1 of 7,300 | 0.01% | 10 of 12,159 | 0.08% |
| 2018 | 0 of 6,927 | 0.00% | 5 of 11,854 | 0.04% |
| 2017 | 1 of 6,558 | 0.02% | 7 of 11,595 | 0.06% |
Showing 10 of 37 years.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| PLCG2 (R665W,L845F) | IBRUTINIB | responsive | chronic lymphocytic leukemia | Cancer Genome Interpreter |
Trial mentions (8)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03787264 | Trial eligibility (AACT) |
| NCT05846399 | Trial eligibility (AACT) |
| NCT04515238 | Trial eligibility (AACT) |
| NCT04883749 | Trial eligibility (AACT) |
| NCT04209621 | Trial eligibility (AACT) |
Showing 5 of 8 trial mentions.
Target-disease associations (422)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Alzheimer disease | nervous system disease | GWAS credible sets |
| Angel-shaped phalango-epiphyseal dysplasia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Ataxia - pancytopenia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 422 associations.
Vendor sourcing (29)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The PLCG2 c.707C>T; p.Pro236Leu variant (rs199760975), to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID: ... | View ClinVar record SCV000885978.2 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1334G>C (p.S445T) alteration is located in exon 14 (coding exon 13) of the PLCG2 gene. This alteration results from a G to C substitution at nucleotide... | View ClinVar record SCV003590869.2 |
| DASA (Brazil) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | NM_002661.5(PLCG2):c.655G>C (p.Asp219His) is a missense variant that results in the substitution of aspartic acid with histidine. This variant is rare in pop... | View ClinVar record SCV007601888.2 |
| Deutsche CLL Studiengruppe (DCLLSG) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. \>1 prior CLL-specific therapy (except corticosteroid treatment administered due to necessary immediate intervention; within the last 14 days before st... | View trial NCT04883749 |
| Deutsche CLL Studiengruppe (DCLLSG) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. (Suspicion of) transformation of CLL (i.e. Richter's transformation, pro-lymphocytic leukemia) or central nervous system (CNS) involvement 2. Progressi... | View trial NCT04515238 |
Showing 5 of 29 sourcing records.
Trial-cited literature (112)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Identification of Renal Transcripts Associated with Kidney Function and Prognosis in ANCA-Associated Vasculitis. | Journal of the American Society of Nephrology : JASN | 2026 | 5 |
| Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia. | Blood | 2026 | 4 |
| Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study. | Blood advances | 2025 | 14 |
| Targeting NADPH Oxidase with APX-115: Suppression of Platelet Activation and Thrombotic Response. | Antioxidants & redox signaling | 2025 | 8 |
| Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma. | Journal of the National Comprehensive Cancer Network : JNCCN | 2025 | 1 |
Showing 5 of 112 papers.
Protein variant mentions (74)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A136T | 1 | 2015 | PMID 25741868 |
| p.A136V | 1 | 2015 | PMID 25741868 |
| p.A308V | 1 | 2015 | PMID 25741868 |
| p.C1249W | 1 | 2015 | PMID 25741868 |
| p.D1140N | 1 | 2021 | PMID 33730844 |
Showing 5 of 74 variants.
Human sample screening reference (1)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.D1140N | TCGA-LUSC | Adenomas and Adenocarcinomas; Squamous Cell Neoplasms; Bronchus and lung | 1 | 504 | 0.20% | 0.04% to 1.12% |
Literature-extracted relations (16)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Tyrosine | Chemical | associate |
Targeting NADPH Oxidase with APX-115: Suppression of Platelet Activation and Thrombotic Response. | 2025 |
| Lymphoma, B-Cell, Marginal Zone | Disease | associate |
Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma. | 2025 |
| Leukemia, Lymphocytic, Chronic, B-Cell | Disease | associate |
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study. | 2025 |
| Colorectal Neoplasms | Disease | associate |
Targeting PLCG2 Suppresses Tumor Progression, Orchestrates the Tumor Immune Microenvironment and Potentiates Immune Checkpoint Blockade Therapy for Colorectal Cancer. | 2024 |
| Neoplasm Metastasis | Disease | stimulate |
Targeting PLCG2 Suppresses Tumor Progression, Orchestrates the Tumor Immune Microenvironment and Potentiates Immune Checkpoint Blockade Therapy for Colorectal Cancer. | 2024 |
Showing 5 of 16 relation assertions.
Organizations publishing (318)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 17 | 2010 to 2023 |
| Dana-Farber Cancer Institute | Other | 8 | 2014 to 2025 |
| Amsterdam University Medical Centers | Hospital | 5 | 2003 to 2024 |
| Boston Children's Hospital | Hospital | 5 | 2014 to 2021 |
| Harvard Medical School | Academic | 5 | 2014 to 2024 |
Showing 5 of 318 organizations.
Where PLCG2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- urinary system disease
404 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and assay-provider ledger.